CG Oncology, Inc. ( ($CGON) ) has released its Q4 earnings. Here is a breakdown of the information CG Oncology, Inc. presented to its investors.

Cretostimogene shows promising efficacy in bladder cancer treatment, with 75.5% complete response rate and sustained duration of over 28 months. CG Oncology, Inc. announced encouraging results ...

CG Oncology’s primary focus has been on advancing ... Targeted approach: The specificity of oncolytic viruses in targeting cancer cells while sparing healthy tissue could potentially result ...

Scotiabank initiated coverage of CG Oncology (CGON) with a Sector Perform rating and $23 price target The company is developing a novel ...

Additionally, CG Oncology will present updates to ongoing clinical trials evaluating cretostimogene across the non-muscle invasive bladder cancer (NMIBC) treatment landscape which are expected to ...

CG Oncology also has a Phase 2 trial ... backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit ...

CG Oncology’s primary focus has been on advancing Creto through ... Targeted approach: The specificity of oncolytic viruses in targeting cancer cells while sparing healthy tissue could potentially ...

About CG Oncology CG Oncology is a late-stage clinical ... bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may ...